ArticleJournal of orthopaedic surgery and research2025
LncRNA GABARAPL2 promotes non‑union long bone fractures by suppressing bone mesenchymal stromal cell osteogenesis.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Neuropilin‑1: Emerging roles in nerve‑vessel‑bone coupling during fracture repair (Review).International journal of molecular medicine · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFracture healing is a complex biological process involving precisely coordinated phases of inflammation, cartilage formation, vascularization, and bone remodeling. Growing evidence suggests that non-coding RNAs play crucial regulatory roles in bone metabolism.
objectiveThis study systematically investigated the role and molecular mechanisms of lncRNA GABARAPL2 (lnc_GABARAPL2) in fracture healing through integrated bioinformatics analysis, clinical validation, and functional experiments, with the goal of identifying novel biomarkers and therapeutic targets for impaired fracture healing.
methodsLnc_GABARAPL2, miR-302a-3p, RUNX2 and OCN mRNA expression levels were quantified by RT-qPCR. Osteogenic differentiation was assessed through Western blot (Collagen I) and spectrophotometric ALP activity measurement and alizarin red S-based mineralization assay. In vitro, lnc_GABARAPL2 expression was modulated in hBMSCs via siRNA knockdown and overexpression vectors, with target interaction validated by dual-luciferase reporter assay. Cell proliferation (CCK-8) and apoptosis (flow cytometry) were assessed. Statistical methods included t-tests, ANOVA, and ROC curve analysis.
resultsLnc_GABARAPL2 expression was significantly elevated in non-union patients and demonstrated excellent predictive performance. Multivariate regression analysis confirmed lnc_GABARAPL2 as an independent predictor of non-union. Functional studies revealed that lnc_GABARAPL2 impaired osteogenic differentiation by suppressing ALP activity and reducing expression of key osteogenic markers RUNX2 and Collagen I, while modulating bone marrow mesenchymal stem cell proliferation and apoptosis through targeting miR-302a-3p.
conclusionThese findings establish that lnc_GABARAPL2 may as a regulator of fracture healing and a promising predictive biomarker for non-union and targeting miR-302a-3p to modulate bone marrow mesenchymal stem cell functions, providing new insights for the development of RNA-based therapeutic strategies for impaired bone repair.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.